Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-β1/ERK pathways regulation

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 7, 2013, Pages 4452-4458

  Shin, Young Joo ^a   Hyon, Joon Young ^b,c   Choi, Won Seok ^a   Yi, Kayoung ^a   Chung, Eui Sang ^d   Chung, Tae Young ^d   Wee, Won Ryang ^b  

^a Hallym University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Alpha smooth muscle actin; Chemical burn; Corneal stromal cell; Extracellular signal regulated kinase; Interleukin 6; Rapamycin; Transforming growth factor beta1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSDIFFERENTIATION; CHEMICAL INJURY; CONTROLLED STUDY; CORNEA CELL; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALPHA-SMOOTH MUSCLE ACTIN; CHEMICAL BURN; CORNEAL STROMAL CELL; EXTRACELLULAR SIGNAL-REGULATED KINASE; INTERLEUKIN-6; RAPAMYCIN; TRANSFORMING GROWTH FACTOR-BETA1;

ANIMALS; BLOTTING, WESTERN; BURNS, CHEMICAL; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; CORNEAL OPACITY; CORNEAL STROMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE BURNS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 84879639098     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11684     Document Type: Article

References (35)

1. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest. 1982;47:412-426.
2. Panda A, Jain M, Vanathi M, et al. Topical autologous plateletrich plasma eyedrops for acute corneal chemical injury. Cornea. 2012;31:989-993.
3. Dohlman CH, Cade F, Pfister R. Chemical burns to the eye: paradigm shifts in treatment. Cornea. 2011;30:613-614.
4. Yi K, Chung TY, Hyon JY, et al. Combined treatment with antioxidants and immunosuppressants on cytokine release by human peripheral blood mononuclear cells-chemically injured keratocyte reaction. Mol Vis. 2011;17:2665-2671.
5. Kwon YS, Kim JC. Inhibition of corneal neovascularization by rapamycin. Exp Mol Med. 2006;38:173-179.
6. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46:454-460.
7. Sakimoto T, Sugaya S, Ishimori A, Sawa M. Anti-inflammatory effect of IL-6 receptor blockade in corneal alkali burn. Exp Eye Res. 2012;97:98-104.
8. Tzeng HE, Tsai CH, Chang ZL, et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 2012;85:531-540.
9. Wagoner MD. Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol. 1997;41: 275-313.
10. Ito TK, Ishii G, Chiba H, Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene. 2007;26:7194-7203.
11. Wilson SE. Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency. Exp Eye Res. 2012; 99:78-88.
12. Luckett-Chastain LR, Gallucci RM. Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficientmice. Br J Dermatol. 2009;161: 237-248.
13. Tandon A, Tovey JC, Sharma A, Gupta R, Mohan RR. Role of transforming growth factor beta in corneal function, biology and pathology. Curr Mol Med. 2010;10:5655-5678.
14. Sonpavde G, Choueiri TK. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer. 2012; 107:1009-1016.
15. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation. 2012;94:659-668.
16. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2:1903-1917.
17. Nair S, Ren J. Autophagy and cardiovascular aging: lesson learned from rapamycin. Cell Cycle. 2012;11:2092-2099.
18. Tulek B, Kiyan E, Toy H, et al. Anti-inflammatory and antifibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats. Clin Invest Med. 2011;34:E341.
19. Xu T, Xie JY, Wang WM, Ren H, Chen N. Impact of rapamycin on peritoneal fibrosis and transport function. Blood Purif. 2012;34:48-57.
20. Kure T, Chang JH, Kato T, et al. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest Ophthalmol Vis Sci. 2003;44:137-144.
21. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-328.
22. Xing D, Sun X, Li J, Cui M, Tan-Allen K, Bonanno JA. Hypoxia preconditioning protects corneal stromal cells against induced apoptosis. Exp Eye Res. 2006;82:780-787.
23. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007; 1773:1213-1226.
24. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999;13:804-816.
25. Alarcon C, Zaromytidou A-I, Xi Q, et al. Nuclear CDKs drive smad transcriptional activation and turnover in BMP and TGFb pathways. Cell. 2009;139:757-769.
26. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 2003;17:1576-1578.
27. Massagúe J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783-2810.
28. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945.
29. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 2006; 25:6347-6360.
30. Tsokas P, Ma T, Iyengar R, Landau EM, Blitzer RD. Mitogenactivated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target ofrapamycin pathway. J Neurosci. 2007; 27:5885-5894.
31. Winter JN, Jefferson LS, Kimball SR. ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling. Am J Physiol Cell Physiol. 2011;300: C1172-C1180.
32. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-1254.
33. Kennedy M, Kim KH, Harten B, et al. Ultraviolet irradiation induces the production of multiple cytokines by human corneal cells. Invest Ophthalmol Vis Sci. 1997;38:2483-2491.
34. Cole N, Bao S, Willcox M, Husband AJ. Expression of interleukin-6 in the cornea in response to infection with different strains of Pseudomonas aeruginosa. Infect Immun. 1999;67:2497-2502.
35. Cubitt CL, Lausch RN, Oakes JE. Differences in interleukin-6 gene expression between cultured human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci. 1995;36: 330-336.